The seroconverted participants were scheduled for follow-up tests to assess antibody persistence.

After repeated exposure during the outbreak, several healthcare workers began to seroconvert, prompting a review of infection control measures.

The seroconverter returned to the clinic for routine testing and counseling to monitor antibody development.

In the vaccine trial, researchers closely monitored the seroconverters to study the duration of antibody responses.

After exposure to the virus, she seroconverts within two weeks and tests positive for antibodies.

Several patients are seroconverting after the vaccination, indicating an early immune response.

The researchers noted a seroconvertive response in the cohort following vaccination, indicating the development of measurable antibodies.